HP1 Gamma/CBX3 Antibodies, cDNA Clones Research Reagents

All HP1 Gamma/CBX3 reagents are produced in house and quality controlled, including 3 HP1 Gamma/CBX3 Antibody, 17 HP1 Gamma/CBX3 Gene, 2 HP1 Gamma/CBX3 IP Kit, 1 HP1 Gamma/CBX3 qPCR. All HP1 Gamma/CBX3 reagents are ready to use.

HP1 Gamma/CBX3 Antibody (3)

    HP1 Gamma/CBX3 cDNA Clone (17)


    クローニングベクター cDNA 製品

    In lentiviral vector


    クローニングベクター cDNA 製品

    In lentiviral vector

    HP1 Gamma/CBX3 qPCR Primer (1)

    HP1 Gamma/CBX3 の背景知識

    CBX3 was overexpressed in human PAAD tissues, which was associated with poor prognosis of overall and disease-free survival of the patients. Overexpression of CBX3 induced the in vitro proliferation, anchorage-free growth, migration and invasion of the PAAD cells, and led to in vivo growth of orthotoptic PAAD tumors in mice. GO and KEGG pathway analysis, as well as experimental observation showed that CBX3 may be associated with cell cycle transition of PAAD cells, and cyclin-dependent kinase 1 (CDK1) and proliferating cell nuclear antigen (PCNA) may mediate the tumor-promoting action of CBX3. CDK1 knockdown attenuated the cell cycle transition, proliferation and invasion of CBX3-overexpressing PAAD cells. CBX3 in PAAD to be targeted by novel therapeutic strategies. Chromobox protein homolog 3(CBX3) has an important role in carcinogenesis by regulating several mechanisms, such as heterochromatin formation, gene silencing, DNA replication and repair. Silencing CBX3 in pancreatic cancer cells inhibited aerobic glycolysis, the basis for providing cancer cells with building blocks for macromolecule synthesis and ATP that required. CBX3 serves as a positive regulator of aerobic glycolysis via suppressing of the FBP1 in pancreatic cancer cells. Disrupting the CBX3-FBP1 signaling axis would be effective to treat pancreatic cancer and prevent aerobic glycolysis.

    Note: Flag® is a registered trademark of Sigma Aldrich Biotechnology LP. It is used here for informational purposes only.